Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 30

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Perineal injury

Recruiting

Study on Patient-Controlled Sedation with Propofol for Women Undergoing Repair of Obstetric Perineal Tears Using Ropivacaine, Lidocaine, and Mepivacaine

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Anhydrous Lidocaine Hydrochloride
  • Sponsor:Region Oestergoetland

Prostate cancer

Recruiting

Study on the Effect of Metastasis-Directed Therapy with Lutetium (177Lu) Zadavotide Guraxetan in Patients with Advanced Prostate Cancer and Up to 5 Progressive Lesions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:UZ Leuven

Testicular germ cell tumour

Recruiting

Study on Preventing Blood Clots in Patients with Advanced Germ Cell Tumors Using Cisplatin and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:Institut Gustave Roussy

HER2 positive breast cancer

Recruiting

Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karolinska University Hospital

Prostate cancer

Recruiting

Study Comparing 177Lu-PSMA-I&T with Apalutamide, Enzalutamide, and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Region Vaesterbotten

Endometrial cancer

Recruiting

Study on Durvalumab for Patients with High-Risk Endometrial Cancer After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Leiden University Medical Center

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Prostate cancer recurrent

Recruiting

Study Comparing Conventional Radiotherapy and PSMA-PET/CT Targeted Treatment with 18F-PSMA-1007 and Gozetotide for Prostate Cancer Recurrence After Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Karolinska University Hospital

Ovarian cancer

Recruiting

Study on the Effectiveness and Safety of Cisplatin and Paclitaxel in Advanced Ovarian Cancer Patients After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Hormone receptor negative HER2 positive breast cancer

Recruiting

Study on Preoperative Treatment for HER2-Negative Breast Cancer Using Pembrolizumab, Paclitaxel, and Carboplatin in Patients Not Responding to Initial Chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Breast cancer metastatic

Recruiting

Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Institut Curie

Menopausal symptoms+1

Recruiting

Study on the Required Dose of Cholecalciferol for Managing Vitamin D Deficiency in Postmenopausal Women

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Colecalciferol
  • Sponsor:Clinica Palacios Madrid S.L.

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.